Natuzzi (NYSE:NTZ) reported quarterly losses of €(0.02) per share. This is a 100 percent decrease over losses of €(0.01) per share from the same period last year. The company reported €116.90 million in sales this quarter. This is a 10.48 percent decrease over sales of €130.58 million the same period last year.
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile For LUMRYZ For Extended-Release Oral Suspension At World Sleep 2023
– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with
